ACELLULAR PERTUSSIS VACCINE

The invention relates to an acellular pertussis (aP) vaccine composition comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 µg per human dose....

Full description

Saved in:
Bibliographic Details
Main Author POOLMAN, JAN THEUNIS
Format Patent
LanguageEnglish
French
Published 12.09.2014
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to an acellular pertussis (aP) vaccine composition comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 µg per human dose. La présente invention concerne une composition vaccinale acellulaire contre la coqueluche (aP) comprenant un toxoïde de la coqueluche (PT) en tant qu'antigènes de Bordetella pertussis, de l'hémagglutinine filamenteuse (FHA), et des fimbriae de types 2 et 3 (FIM), et facultativement de la pertactine (PRN), les FIM étant présents en une quantité de 12 à 100 µg par dose humaine.
Bibliography:Application Number: WO2014EP54379